Coherus Biosciences. Every tracked FinTwit mention of $CHRS, newest first. 7 mentions since the first on Sep 24, 2025. See the price chart.
June 2026 · 3 mentions
Jun 26
Jacob Plieth — $CHRS announced a clinical-trial collab on 23 Jun, and that's apparently slotted into Zumutor's existing IND. Did Zumutor fail to sign a clinical-trial collab with $MRK?↗
Jun 26
Jacob Plieth — Zumutor initially was to test ZM008 + Keytruda, but now it's ZM008 + Loqtorzi $CHRS https://t.co/8xdLcK44u1↗
Jun 26
Jacob Plieth — Some curious clinical trial design changes slipped out in the past few days by Zumutor / $CHRS & $MRNA↗
March 2026 · 1 mention
Mar 16
Jacob Plieth — Since my 2024 look at CCR8 a lot has happened: $BMY $GILD $ABBV upsized; $ONC Bayer $ZLAB (& soon $AMGN?) discontinued. @BatirtzeAreitio investigates, via @ApexOnco -> https…↗
September 2025 · 1 mention
Sep 24
Jacob Plieth — Apparently #SITC25 is hosting a webinar on development of anti-CCR8 MAbs - mechanisms & clinical results. 22 Oct 2025 $CHRS $BMY $ABBV $RHHBY $AMGN $GILD $BGNE $FGEN $BNTX↗
July 2025 · 2 mentions
Jul 11
Jacob Plieth — I scoured the FDA's cache of CRLs and found six that relate to novel oncology drugs. Includes first formal disclosure that Akeso's penpulimab got a CRL in 2024. Via @ApexOnco ->…↗
Jul 10
Jacob Plieth — FWIW, the CRLs in FDA's newly released list concerning oncology drugs (excl generics) are for:
- penpulimab
- torpialimab $CHRS
- Fotivda
- Trodelvy $GILD
- Vyloy $ALPMF↗